Phase III · Positive results published · US-approved
Does daraxonrasib prolong survival in previously treated metastatic pancreatic cancer?
RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of Daraxonrasib (RMC-6236) Versus Investigator's Choice of Standard of Care Therapy in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Not an individual treatment recommendation. This page summarizes a study with published results; suitability, approval, and access require clinician judgment.
For patients
Patient question
Does daraxonrasib prolong survival in previously treated metastatic pancreatic cancer?
In RASolute 302, oral targeted daraxonrasib was compared with standard treatment options in people with metastatic pancreatic cancer who had already received prior therapy.
What did it show?
Reported median overall survival was 13.2 months with daraxonrasib and 6.7 months in the comparison group. Time to progression and tumor response rates also favored daraxonrasib.
These findings mark an important advance in previously treated metastatic pancreatic cancer.
They do not apply directly to every person with pancreatic cancer. Prior therapy, overall health, molecular features, and access must be considered together.
US regulatory approval does not mean the same use is licensed or reimbursed in Türkiye.
Median overall survival (overall trial population)
These are group medians — not one person’s survival rising from 6.7 to 13.2. In the dual-primary RAS G12 analysis, control median overall survival was 6.6 months. Hazard ratios must not be read as “percent longer life” on the patient view.
Why does this result matter?
This is a randomized phase III result. Median overall survival, progression-free time, and tumor response rates favored daraxonrasib.
The findings mark an important treatment advance in previously treated metastatic pancreatic cancer.
Suitability depends on prior therapy, overall health, tumor molecular features, and local access. US approval is not access in Türkiye.
What did this study not prove?
Results do not apply directly to every person with pancreatic cancer.
They are not automatic first-line care for resectable early disease or every untreated patient.
RAS G12 results are not the same as non-G12 mutations (e.g. Q61H) or “all metastatic PDAC.”
Türkiye licensing and SGK coverage do not follow automatically from US approval.
Which patients does this study cover?
Patients enrolled
- Metastatic pancreatic cancer
- People previously treated with systemic therapy, as in the trial
- US label also includes some people who are not candidates for multiagent systemic therapy (clinician judgment; access in Türkiye separate)
Who cannot directly use these results?
- Early disease limited to the pancreas that can still be removed surgically
- Not an automatic first-line choice for every untreated patient
- Non–RAS G12 or molecularly different tumors are not automatically the same result
- Does not mean licensed or SGK-covered in Türkiye
Read the previously treated trial population and the FDA label text separately. Molecular subgroup (especially RAS G12) should be clarified in clinician assessment.
Is this standard care today?
It is an FDA-approved option in the US (26 August 2026). That does not mean it is licensed or SGK-covered in Türkiye, or automatic standard care everywhere.
The trial’s previously treated population and the FDA label text (≥1 prior systemic therapy or not a candidate for multiagent therapy) should be read separately.
Is this available in Türkiye?
US approval does not mean the same use is licensed or reimbursed by SGK in Türkiye.
Daraxonrasib licensing, reimbursement, and site access in Türkiye must be verified from current official sources.
Scientific study details
- Study name
- RASolute 302
- Clinical trial number
- NCT06625320
- Study type
- Phase III
- Recruitment (registry)
- Completed; results published
- Disease studied
- Trial (NCT06625320): previously treated metastatic PDAC after progression on ≥1 line. Overall n=500 (248/252). FDA indication is read separately (≥1 prior therapy or not a multi-agent chemo candidate).
- Investigational treatment
- Daraxonrasib 300 mg orally once daily (RMC-6236)
- Comparator approach
- Investigator’s choice of SoC chemotherapy: gemcitabine+nab-paclitaxel (GnP), mFOLFIRINOX, nal-IRI+5-FU/LV, or FOLFOX
- Primary endpoint
- Dual primary: OS and BICR-PFS in the RAS G12 subpopulation. Key secondary: OS/PFS in the overall population; ORR; QoL
- Publication status
- Peer-reviewed NEJM 2026 phase III results (DOI 10.1056/NEJMoa2605555).
- Approval status for the approach studied in this trial
- FDA approval — 26 August 2026 (US). Indication: metastatic pancreatic adenocarcinoma in adults after ≥1 prior systemic therapy or who are not candidates for multiagent systemic therapy. Label is not limited to RAS mutation. Türkiye license/SGK are separate.
- Results status
- Results disclosed / being followed
For information only. A treatment studied in a clinical trial should not be treated as standard care until results and relevant approvals are assessed.
Landmark Atlas
If this study changed the standard of care, its primary home is the Atlas: